Chief Commercial Officer and Executive Vice President, Business Development · ZEVRA THERAPEUTICS, INC. (ZVRA)

Joshua Schafer

FY2023 is the first fiscal year CompBrief holds for Joshua Schafer as a named executive officer of ZEVRA THERAPEUTICS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,814,465

Salary $452,333Stock awards $0Bonus $100,000

5th of 6 named executive officers at Zevra Therapeutics by FY2023 total.

6 named officers on file for ZEVRA THERAPEUTICS, FY2023

Joshua Schafer’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ZEVRA THERAPEUTICS’s whole pay program stands against its peers

  • ZEVRA THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ZVRA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 3, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Joshua Schafer’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Joshua Schafer compensation by year

ZEVRA THERAPEUTICS Summary Compensation Table · the one fiscal year held
In US dollars, as ZEVRA THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$452,333
Bonus$100,000
Stock awards$0
Option awards$1,049,397
Non-equity incentive$200,535
Pension and deferred compensation$0
All other$13,200
Total$1,814,465

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ZEVRA THERAPEUTICS, INC. DEF 14A filed April 3, 2024, accession 0001437749-24-010874, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ZEVRA THERAPEUTICS, INC. filed document, accession 0001437749-24-010874. Every figure is read from that document and cited to the page and table it appears in. Filed April 3, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option300,000—$4.54

Per the Outstanding Equity Awards at Fiscal Year-End table in ZEVRA THERAPEUTICS, INC.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

13 Form 4 lines since the FY2023 proxy (filed April 3, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-02-03Sale10b5-110,500$9.1962,278
2026-01-31Exercise or conversion10b5-135,334—72,778
2026-01-31Exercise or conversion derivative10b5-135,334$0.0035,333
2026-01-30Exercise or conversion10b5-111,333—40,819
2026-01-30Sale10b5-13,375$8.8337,444
2026-01-30Exercise or conversion derivative10b5-111,333$0.0022,667
2026-01-29Grant or award derivative10b5-137,500$0.0037,500
2026-01-29Grant or award derivative10b5-175,000$0.0075,000

The 8 most recent of 13 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ZEVRA THERAPEUTICS’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Richard PascoeFormer Chief Executive Officer and Director$4,122,558
Travis MickleFormer President, Chief Executive Officer and Director$3,593,438
Neil McFarlanePresident, Chief Executive Officer and Director$3,445,231
R. LaDuane CliftonChief Financial Officer, Secretary and Treasurer$2,263,257
Joshua Schafer · this pageChief Commercial Officer and Executive Vice President, Business Development$1,814,465
Christal MickleFormer Interim Chief Executive Officer$1,669,956

The full ZEVRA THERAPEUTICS compensation record

free company brief

This page is one person within ZEVRA THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ZEVRA THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Joshua Schafer's compensation dossier · One-time report. No refunds.